Including the ones nobody will sell you, the ones where the marketing has outrun the data, and the ones that are not legal to compound right now. Every page states its evidence grade and exact regulatory status. Free to read, nothing to sign up for.
| Grade | Means | How much of this category |
|---|---|---|
| A | Randomised controlled trials in humans | A small minority |
| B | Human observational, cohort or open-label data | Some |
| C | Animal or in vitro studies only, no human trials | Most of it |
| D | Plausible mechanism, no direct outcome data | More than you would think |
Being upfront: a great deal of this category is Grade C. Labelling it honestly is what makes the Grade A pages worth trusting.
Signals, not supplements. Why that changes what to expect.
What April and July actually changed, and what did not.
Purity is not sterility. The gap that sends people to hospital.
Vial size, water, dose, and exactly what to draw.
Signals your pituitary rather than supplying the hormone.
The strongest evidence here, and one real limitation.
Heavily advertised, still on the FDA restricted list.
Two forms that are not interchangeable, and nobody explains why.
First generation secretagogues. Cortisol is the catch.
Potent, and it stops working. Desensitisation is documented.
The one with an acute risk, not just a theoretical one.
A local signal, sold as a systemic injection.
Five positive Phase 3 trials. Not approved anywhere on earth.
What changed in February 2025 and why compounding closed.
Same position, slightly earlier on the same timeline.
The amylin half of CagriSema. Novo asset, not approved.
GLP-1 plus glucagon. Notable for the liver disease data.
Encoded in mitochondrial DNA. Interesting, and mostly in mice.
Real trials in rare disease. Not the use it is sold for.
The rare case where trials ran and the results disappointed.
Not a peptide. Mouse data only, sold as if otherwise.
The exercise mimetic that never translated out of mice.
The most searched compound in the category. The honest status.
A fragment of a real protein, sold on the parent's research.
FDA staff found no human studies. The panel recommended it anyway.
Good topical evidence, much weaker injected. The two get conflated.
Decades of Russian clinical use, almost none readable in English.
Same evidence problem as Semax, one step further along.
The widest gap between marketing and evidence on the list.
Designed to trigger cell death. Never tested in a human.
The only compound the FDA panel turned down. Why that matters.
Where the evidence is, and why the infusion feels like that.
Not a peptide. A porcine brain extract, and Cochrane is unconvinced.
Approved in 30+ countries. Not here, for commercial reasons.
Genuinely double-edged. Implicated in rosacea and psoriasis.
Vasoactive is the mechanism, not the branding. Blood pressure matters.
FDA approved as Vyleesi. Strong data, substantial side effects.
A real drug. The love hormone story is much messier than you have heard.
Legitimate uses, and one famous claim that has never held up.
Real science, upstream of everything. Wrong use case.
Documented harm, including changes to existing moles.
Afamelanotide is a real drug. What you are offered is not it.
A face cream ingredient that ended up on an injectable price list.
Everything available now, with prices and every size.